

For Immediate Release

**Alembic Pharmaceuticals Ltd.
Consolidated Results for quarter ended 31.12.2011**

**Revenues up 15 % at Rs 383 crores against Rs. 332 crores in PY
PBT up 18 % at Rs 53.54 crores against Rs. 45.40 crores in PY**

Editors Synopsis

Quarter ended 31st December 2011

- **Net sales up 15 % at Rs 383 crores against Rs. 332 crores in corresponding quarter last year**
- **Domestic formulations up 8 % at Rs. 199 crores against Rs. 184 crores in corresponding quarter last year**
- **International Generics up by 13 % to Rs. 58 crores vis-à-vis Rs. 52 crores last year**
- **Profit before tax up by 18 % at Rs. 53.54 crores against Rs. 45.40 crores in corresponding quarter in last year**
- **2 ANDA approvals received in current quarter. 3 DMF's filed during the quarter.**

Nine month ended 31st December 2011

- **Net sales grew by 24 % - Domestic by 13 % and Exports by 46 %**
- **Profit before tax up by 43 % at Rs. 134.05 crores against Rs. 93.82 crores in last year**
- **Profit after tax up by 46 % at Rs. 109.83 crores against Rs. 75.11 crores in last year**
- **EBIDTA margins 16 % at Rs. 179.30 crores against 15 % at Rs. 133.11 crores in last year**
- **41 Cumulative ANDA filings, 17 approvals in place. Cumulative DMF filings at 59.**

Vadodara, 8th February 2012

Alembic Pharmaceuticals Limited, the pharmaceutical major, today reported a 15% increase in revenues to Rs 382.82 crores for the quarter ended 31st December 2011, compared to Rs 331.54 crores in the corresponding quarter last year.

The Company posted an impressive 18% growth in profit before tax at Rs. 53.54 crores for the quarter ended December 2011 against Rs 45.40 crores posted in corresponding quarter last fiscal.

International Business

International Generics to the regulated markets grew by 13% to Rs. 58.45 crores from Rs. 51.72 Crores over the corresponding quarter last year.

Formulations sales to ROW markets amounted to Rs. 15.60 crores against Rs. 15.04 crores in corresponding quarter last year.

Export of API products grew by 112% to Rs. 89.90 crores from Rs. 42.38 crores over corresponding quarter last year.

Cumulative DMF filings at 59. Cumulative ANDA filings at 41. Cumulative ANDA approvals now stands at 17.

Domestic Formulation Business

The domestic formulation business posted sales of Rs. 198.78 crores against Rs. 184.24 crores registering 8% growth over the corresponding quarter last year.

Alembic has maintained a market share of 1.75%.

Alembic has four brands in the list of top 300 brands of the industry i.e. 'Azithral' , 'Roxid', 'Althrocin', and 'Wikoryl'.

Domestic API Business

Domestic API sales degrew 44% at Rs. 18.73 crores against Rs. 33.68 crores of PY.

Summary of total revenue (consolidated) for the quarter:

(Rs. in Lacs)

Particulars			
	Q3 FY12	Q3 FY11	% Change
Formulation			
Domestic	19878	18424	8%
International Branded	1560	1504	4%
International Generics	5845	5172	13%
API			
Domestic	1873	3368	-44%
International	8990	4238	112%
Export incentives	136	448	
Total	38282	33154	15%

The Profit break-up for the quarter:

(Rs. in Lacs)

Particulars	Consolidated		
	Q3 FY12	Q3 FY11	% Change
Operating Income	6848	5943	15%
Profit Before Tax	5354	4540	18%
Net Profit after Tax	4423		

The previous year's figures are approx. and unaudited numbers of relevant businesses which were then part of Alembic Limited. These are given just for comparison purpose.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in Macrolides segment of anti-infective drugs in India.

Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

For more information:

Alembic Pharmaceuticals Limited

Mitanshu Shah

0265 – 3007630

mitanshu.shah@alembic.co.in